Online Summary
Correction to: Cohen AT. Long-term benefits of preventing venous thromboembolic events. Curr Med Res Opin 2012;28:877-89
This article refers to:
Correction to: Cohen AT. Long-term benefits of preventing venous thromboembolic events. Curr Med Res Opin 2012;28:877-89
The authors have been made aware of a dosing error regarding edoxaban in the Hokusai-VTE trial (clinicaltrials.gov; NCT00986154) detailed in Table 4 (p885) and in the text on p886.
Patients treated with edoxaban in Hokusai-VTE receive a dose of 60 mg once daily (administered as two tablets of 30 mg) and not, as indicated, 30 mg twice daily.
This error did not affect any of the study results or conclusions.